Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migrain
Here's Why AbbVie (ABBV) Fell More Than Broader Market
06:46pm, Tuesday, 17'th Jun 2025
In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
11:31am, Tuesday, 17'th Jun 2025
Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
10:31am, Tuesday, 17'th Jun 2025
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow
06:42am, Tuesday, 17'th Jun 2025
AbbVie remains a Buy despite venetoclax's MDS trial failure, as this setback has minimal impact on current revenue and growth outlook. SKYRIZI and RINVOQ are successfully replacing HUMIRA's lost reven
Here's Why AbbVie (ABBV) is a Strong Value Stock
10:45am, Monday, 16'th Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
10:11am, Monday, 16'th Jun 2025
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
AbbVie says blood cancer drug fails late-stage trial
09:12am, Monday, 16'th Jun 2025
AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of overall survival in a late-stage trial.
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
09:00am, Monday, 16'th Jun 2025
NORTH CHICAGO, Ill. , June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagno
AbbVie: Margin Clarity, Dividend Durability Awaited
05:05am, Monday, 16'th Jun 2025
AbbVie's top line is stable post-Humira, with Skyrizi and Rinvoq driving growth, but margin recovery remains uncertain and slow. Pipeline and acquisitions support long-term growth, but macro risks lik
AbbVie Moves From Blockbuster Loss To Market Domination
01:29am, Monday, 16'th Jun 2025
Skyrizi and Rinvoq are rapidly replacing Humira, generating over $5 billion in Q1 2025 alone. From migraine to Parkinson's and obesity, AbbVie is building dominant franchises across multiple high-grow
AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend Growth
08:30am, Sunday, 15'th Jun 2025
AbbVie is undervalued, trading at under 16x 2025 earnings, despite robust EPS growth, a strong pipeline, and successful Humira diversification. Skyrizi and Rinvoq are driving immunology revenue, expec
AbbVie's Post-Humira Strategy Is Paying Off For Investors
07:11am, Sunday, 15'th Jun 2025
AbbVie offers a compelling blend of high yield, consistent dividend growth, and strong financials, making it attractive for income-focused investors. The company has successfully transitioned from Hum
Calls of the Day: Netflix, NRG Energy, Air Products, and Abbvie
01:57pm, Friday, 13'th Jun 2025
The Investment Committee debate the latest Calls of the Day.
Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight
01:00pm, Thursday, 12'th Jun 2025
The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibito
